Coverage generosity of novel anti-rheumatic drugs in Medicare Advantage and stand-alone Part D plans

The authors aimed to evaluate the coverage of self-administered disease-modifying anti-rheumatic drugs (DMARDs) in Medicare Part D plans from 2022 to 2026. They found that while coverage was high for some TNF inhibitors and a JAK inhibitor, significant gaps existed for other DMARDs, particularly abatacept, with only a small percentage of plans covering all drug classes. This variability in coverage highlights potential barriers to accessing effective rheumatoid arthritis treatments, necessitating further research on the implications of these formulary exclusions.